glp-1 discontinuation rates Proportion of Patients Who Discontinued RA Therapy, n=4791 High Discontinuation Rates of GLP-1

however, the definitive effects of exenatide in such patients were still inconclusive [81]

Instead in patients with eGFR 60 ml/min/1.73m 2 , 3060, and 60 ml/min/1.73 m 2

Liraglutide leads with 35.5% market share due to its established clinical evidence and proven safety profile, while online pharmacy distribution dominates as patients seek convenient access to these premium therapies

The future of pharmacy benefits isnt just about managing costs, its about making smarter, more sustainable choices for everyone.

This helps reduce appetite, increase feelings of fullness after meals, and support sustainable weight loss